San Diego, CA, United States of America

Yangzhou Wang

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Crown Bioscience Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yangzhou Wang. Retrieved from https://idiyas.com/inventor/yangzhou-wang-ikeqjy82

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yangzhou Wang - Innovator in Anti-CD4 Antibodies

Introduction

Yangzhou Wang is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of anti-CD4 antibodies. His work has implications for various therapeutic applications, showcasing his expertise and innovative spirit.

Latest Patents

Yangzhou Wang holds a patent for anti-CD4 antibodies. The patent encompasses isolated polynucleotides encoding these antibodies, pharmaceutical compositions that include them, and their various uses. This invention represents a crucial advancement in the treatment of diseases where CD4 plays a pivotal role.

Career Highlights

Yangzhou Wang is currently associated with Crown Bioscience Inc., a company known for its focus on preclinical research and development services. His role at the company allows him to leverage his expertise in antibody development and contribute to groundbreaking research.

Collaborations

Yangzhou has collaborated with esteemed colleagues such as Ziyong Sun and Wencui Ma. These partnerships enhance the research environment and foster innovation within the field.

Conclusion

Yangzhou Wang's contributions to the development of anti-CD4 antibodies highlight his role as a key innovator in biotechnology. His work not only advances scientific knowledge but also has the potential to impact therapeutic strategies significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…